Results 201 to 210 of about 66,883 (257)

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

Advanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai, Keyu Wang, Jiali Fang, Shaorui Jia, Yansong Shi, Wanfeng Gao, Xinpeng Liu, Jiaqiang Li, Zenghui Cui, Yazhi Qian, Xiaosu Chen, Dan Ding, Xuetao Cao   +12 more
wiley   +1 more source

A novel proteolysis-targeting chimera strategy targeting multiple immune checkpoints containing ITIMs enhances antitumor immunity. [PDF]

J Pharm Anal
Qiu YY, Wang ZW, He L, Shi GG, Li ZZ, Ma SX, Yu D, Du HC, Xie F, Zhang C, Zhang YQ, Li M, Li WN.   +12 more
europepmc   +1 more source

Targeting Lactate‐Driven Stromal Autophagy via MCT1 Disrupts the Immunosuppressive Niche and Sensitizes Pancreatic Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
Tumor‐derived lactate activates PSCs through MCT1‐mediated Vps34 lactylation and autophagy. These activated PSCs secrete CXCL9/10, upregulating PD‐1 on CD8+ T cells via the CXCR3/STAT3 axis to foster immunosuppression. Disrupting this metabolic crosstalk by targeting MCT1 effectively sensitizes pancreatic cancer to PD‐1 blockade, presenting a promising
Wenfeng Zhuo, Rong Hu, Yuhang Hu, Ping Hu, Shengbo Han, Guozheng Lv, Zhu Zeng, Yong Zhao, Yang Li, Yan Huang, Yingsong Zhao, Hongda Wang, Guangyu Zhao, Eryang Zhao, Gang Zhao   +14 more
wiley   +1 more source

Selective Targeting of Immune Checkpoints HLA-G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity. [PDF]

Adv Sci (Weinh)
Jacob LJ, Tamir L, Abdeen M, Tamir A, Aronin A, Bloch I, Kahn R, Pecker I, Tykocinski M, Huls G, Pereg Y, Chajut A, Bremer E.   +12 more
europepmc   +1 more source

Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor

Advanced Science, EarlyView.
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao, Dongdong Liu, Haishan Gao, Chenyang Qin, Wen Zhang, Ziyun Lu, Dongxia Tan, Yuxiu Qu, Yusong Liu, Zhiran Zou, Hongtao Yu, Wei Qi   +11 more
wiley   +1 more source

CD160-Derived Peptide as a Bidirectional Inhibitor Toward Immune Checkpoints BTLA/HVEM and HVEM/LIGHT. [PDF]

J Med Chem
Lipińska M, Ciura P, Gumpelmair S, Sikorska E, Kuncewicz K, Sieradzan AK, Steinberger P, Wardowska A, Spodzieja M.   +8 more
europepmc   +1 more source

Cracking Chordoma's Conundrum: Immune Checkpoints Provide a Potential Modality. [PDF]

Int J Med Sci
Liu W, Regmi M, Chen X, Liu S, Xiong Y, Dai Y, Wang Y, Yang J, Yang C.   +8 more
europepmc   +1 more source

Immunohistochemical Profiling of Immune Checkpoints in Chronic Hepatitis B Liver Tissue. [PDF]

Pathogens
Panão-Costa J, Oliveira RC, Teixeira P, Caramelo F, Cipriano MA, Borges O, Carvalho A.   +6 more
europepmc   +1 more source

Targeting immune checkpoints as a new therapeutic strategy for intra-hepatic cholangiocarcinoma. [PDF]

Bioimpacts
Khedr EG, Abo Seif MA, Abdelzaher OF, Mehany ABM, El-Feky OA.   +4 more
europepmc   +1 more source